stockrow
Friday 6 November 2026
Export ORKA’s income statement to Excel — free account
Oruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
102.68
6.66
+6.94%
Follow ORKA
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (18.30%) | (27.50%) | (24.86%) | (25.92%) |
+8 more TTM periods Free account |
|
| (17.76%) | (26.37%) | (23.84%) | (23.11%) | ||
ROIC |
(40.22%) | (85.17%) | (56.55%) | (55.54%) | |
Return on Tangible Assets |
(15.42%) | (30.68%) | (32.07%) | (31.90%) | |
Free Cash Flow per Share |
(1.61) | (1.65) | (1.94) | (1.92) | |
Free Cash Flow |
(101.15) | (91.19) | (88.42) | (84.60) | |
Capital Expenditures |
(0.23) | (0.27) | (0.21) | (0.16) | |
| Other line items | |||||
Cash ROIC |
(5.09%) | (10.41%) | (10.93%) | (10.12%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.76 | 0.78 | 0.84 | 0.79 | |
Depreciation/Fixed assets |
(10.80) | (11.14) | (17.08) | (25.75) | |
Capex/Depreciation |
0.08 | 0.08 | 0.04 | 0.03 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.61) | (1.65) | (1.93) | (1.92) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026